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Abstract
Background: Timely detection of treatment failure with subsequent switch to second-line regimen reduces mortality
among HIV infected people on antiretroviral therapy (ART). This paper aims to investigate the detection of immunological
treatment failure and switch rate to second line regimen in Ethiopia.
Methods: A retrospective cohort study was conducted among HIV infected patients (age > 15 years) who initiated ART
between 2007 and 2009. The required data were collected from patient registers and formats. Data were entered and
validated using EpiData software and then exported to SPSS version 20.0 for analysis. Odds ratio with 95 % CI was used to
assess whether immunological treatment failure was associated with experiencing unfavorable treatment outcomes
(death or lost to follow up).
Results: Records of 293 patients were reviewed with a total of 1545 Person-Years of Observation (PYO). The
median baseline CD4 count was 115 cells/mm3 (IQR: 64–176). A total of 46 (15.7 %) patients experienced
immunological treatment failure. The immunological failure rate was 3.0 per 100 PYO. Treatment was switched
to second-line regimen for six (2.1 %) patients. The rate of treatment switch to second-line regimen for any
purpose was 0.4 per 100 PYO. Out of the six patients, only two fulfilled the WHO criteria for immunological
failure; the remaining four patients had their treatment switched to second-line regimen for other purposes.
This implies that only 4.3 % (2/46) of patients with immunological failure were switched to second-line regimen. The risk
of experiencing unfavorable outcome was 5.75 (95 % CI 1.11, 29.8) times higher among those who had immunological
failure than their counterparts after adjusting for baseline CD4 count.
Conclusions: Majority of patients with immunological treatment failures were not detected and continued taking the
failed regimen. Further studies are required to assess and explore why patients with immunological failure are
not switched to second-line regimen as per the standard protocol.
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Background
Approximately 35.0 million people were living with HIV
in the world by the end of 2013. In the same year, 12.9
million people living with HIV were receiving antiretro-
viral therapy (ART) globally, out of which 11.7 million
were in low and middle-income countries representing
36 % of the 32.6 million people living with the virus in
low and middle-income countries [1].
As the ART uptake increases, the emergence of resist-
ant viruses resulting in treatment failure is inevitable
and should be anticipated proactively. As a result pa-
tients need to be switched to second-line regimen in
order to have a sustained viral suppression [1–3].
The diagnosis of treatment failure is guided by viral
load testing in high income countries; however, this is
not the case in most low income countries because viral
load testing is costly and requires advanced infrastruc-
tures [2, 3]. Cognizant of this, WHO has designed rela-
tively simple criteria to diagnose treatment failure using
immunological and clinical criteria. The definitions of
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immunological failure are either fall of CD4 count to
baseline (or below) or 50 % fall from on-treatment peak
value or persistent CD4 levels below 100 cells/mm3 [3].
Even though the immunological criteria to diagnose
treatment failure was documented to have low positive
predictive value and low sensitivity, the extent to which
it is being utilized in health facilities has not been well
studied in Ethiopia. Thus, in this study we aim to inves-
tigate the rate of immunological failure, its detection
and switch rate to second-line regimen.
Methods
Study setting
The study was conducted in Federal Police Referral
Hospital (FPRH). ART program was launched in the hos-
pital in parallel with other public health facilities. FPRH
started to provide ART service in 2005. The hospital also
provides HIV prevention, care and support services.
Treatment initiation, eligibility criteria and service delivery
model
The ART guideline in Ethiopia is based on the 2008
WHO recommendations. However, there were technical
updates as an addendum to the national ART guideline
at different times based on the 2010 and 2013 WHO
recommendations [4].
According to the national ART guideline, eligibility for
initiation of ART is determined using CD4 count and
WHO clinical stage. When CD4 count is not available,
patients with WHO clinical stage III and IV conditions
are eligible for treatment. In addition, patients with
WHO clinical stage II conditions with Total Lymphocyte
Count (TLC) less than 1,200 cells/ml are considered for
treatment [4].
Whereas in the presence of CD4 count, WHO clin-
ical stage III patients with CD4 cell count less than
350 cells/mm3 and all patients with WHO clinical
stage IV conditions are eligible for treatment. In
addition, patients with WHO clinical stage I and II
with CD4 cell count below 200 cells/mm3 are eligible
for treatment [4]. There was no major change in eligi-
bility criteria until 2013 which is beyond the period
for cohort selection for this study.
In FPRH, the HIV chronic care services are delivered
by trained nurses and health officers. Physicians are
available for consultation in case of complications and
for patients with advanced disease.
Study design, study population and sampling procedure
This study was a retrospective cohort study of HIV-
infected patients who started ART at the FPRH. The
intended service users in FPRH include active and re-
tired police members, their dependents, civilian workers
and other civilian residents in the surrounding area.
The current study included patients (age > 15 years)
who started ART between January 2007 and December
2009, had follow up in the facility for at least 24 months
and had at least four CD4 measurements including the
baseline measurement. Transfer-in cases were also
included in the study provided that they fulfilled all the
other inclusion criteria. The primary end-point was im-
munological failure using the WHO definitions as
outlined above.
In the present study, baseline CD4 count was a
measurement occurring closest to the date of starting
ART, within a window of 6 months prior to the start
of ART to 1 week after ART initiation.
Data collection procedure
A structured data abstraction format was used to collect
the data from patients’ cards and registers. The format
was developed using the standardized patient monitor-
ing formats and registers. Patient intake form, follow up
card and ART registers as well as the electronic informa-
tion database were used as data sources. Other clinical
charts including laboratory test results were also used to
collect the CD4 cell counts.
Unique ART number and the new Health Management
Information System (HMIS) card number were used to
identify individual patient cards or their data in the elec-
tronic database. Socio-demographic characteristics, base-
line and follow up clinical and laboratory data, and
treatment outcomes were collected from patient cards.
Two data clerks and one case manager (adherence
supporter) from FPRH were trained and hired as data
collectors. The federal police health service directorate
data manager was hired as data collection supervisor.
All completed formats were examined for clarity and
consistency by the supervisor and finally by the
researchers. The data were collected in June /2014.
Data management and analysis
Data were entered, and validated using EpiData software
version 3.1. Each format was given a unique identifica-
tion number for data entry. A cleaned and compiled data
were exported for analysis to SPSS version 20. Propor-
tions, means, medians with measures of dispersion were
calculated as deemed necessary. Odds ratios with 95 %
CIs were used to assess whether immunological treat-
ment failure was associated with experiencing unfavor-
able treatment outcomes (death or loss to follow up).
For statistical tests, level of significance was set at type-I
error of 0.05.
Ethical considerations
Ethical clearance was obtained from Addis Continental
Institute of Public Health and Mekele University joint
Institutional Review Board. Permission was obtained
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from Federal Police Health Service Directorate and
FPRH administration. In Ethiopia, patients are not re-
quested for consent to use an already existing data
within health facilities. All the information obtained dur-
ing the course of the study was held in a confidential
manner. The data were kept in a locked cupboard. Pa-
tient names were not recorded or linked to the results of
the study.
Result
Selected charts for review
Within the period of interest, there were a total of 741
patients who initiated ART in the hospital. However,
only 293 charts fulfilled the inclusion criteria and were
included for data abstraction. Figure 1 depicts the result
of the patient card selection using flow chart.
Baseline characteristics of the study cohort
Records of 293 patients were reviewed with a total of
1545 Person-Years of Observation (PYO). All the study
cohorts initiated treatment between January 2007 and
November 2009. Most (58.4 %) of the study cohorts
started ART in the month of knowing their HIV infec-
tion status. At baseline, the mean age was 36.7 years
(SD = 8.6 years) and 64.2 % were males while the sex of
0.7 % were not recorded. The median baseline CD4 count
was 115cells/mm3 (IQR: 64–176). Majority (75.8 %) of the
patients had baseline CD4 count less than 200cells/mm3.
In relative terms, the common regimen was D4T/3TC/
NVP accounting for 39.2 %. Treatment was switched to
second-line regimen for 2.1 % of the cases. Substitution to
different drugs within first line regimen was observed for
30.7 % of the cases. Similar results for other variables
and disaggregated by immunological failure status is
shown in Table 1.
Cohort period and treatment outcome
The median retrospective follow up period was
70 months (IQR: 54–76 months). By the time the data
collection terminated, 81.2 % were actively on treatment,
4.1 % were lost or dropped from care, 2.0 % died and
the rest 12.6 % were transferred out to another facility.
A total of 46 (15.7 %) patients experienced immuno-
logical treatment failure. This translates to immuno-
logical failure rate of 3.0 per 100 PYO. Out of these 46
patients with immunological failure, the reasons for the
failure were drop by more than 50 % of the pick value
attained in 45.3 % of the cases, persistently below
100 cells/mm3 after taking ART for at least 24 weeks
in 13.3 % of the cases and CD4 count below the
baseline value in another 45.3 % of the cases.
Treatment was switched to second-line regimen for
six (2.1 %) patients. The rate of treatment switch to
second-line regimen for any purpose was 0.4 per 100
PYO. Out of the six patients only two fulfilled the WHO
criteria for immunological failure; the remaining four
patients had their treatment switched to second-line
regimen for other purposes such as regimen simplifica-
tion. This implies that only 4.3 % (2/46) of immunologic-
ally failed patients were switched to second-line regimen.
Fig. 1 Selection steps for the analyzed charts in Federal Police Referral Hospital for patients who initiated ART between January 2007 and
December 2009
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Effect of immunological treatment failure on treatment
outcome
Next we examined if immunological treatment failure
was associated with final follow up status. Accordingly,
we found that the proportion of patients experiencing
unfavorable treatment outcome was higher among pa-
tients with immunological treatment failure than their
counterparts. For instance, the proportion of those who
died was 6.5 % among patients who had immunological
failure whereas it was 1.2 % among the other group
(Fig. 2).
When the outcome was dichotomized by taking dead
and lost to follow up or drop as unfavorable outcome
and the rest as favorable outcome, it was found that the
Table 1 Baseline characteristics of the study cohort
Variable Immunologic treatment failure Total (%)
Yes (%) No (%)
Sex Male 32 (17.0) 156 (83.0) 188 (64.2)
Female 14 (13.6) 89 (86.4) 103 (35.2)
NR 1 (50.0) 1(50.0) 2 (0.7)
Age (In years), at Month0 Mean, SD 34.6, 7.5 36.6, 8.5 36.7, 8.6
15–34 23 (18.1) 104 (81.9) 127 (43.5)
35–44 16 (13.3) 104 (86.7) 120 (41.1)
> = 45 6 (13.3) 39 (86.7) 45 (15.4)
Original First Line Regimen D4T/3TC/NVP 15 (13.0) 100 (87.0) 115 (39.2)
D4T/3TC/EFV 59 (78.7) 16 (21.3) 75 (25.6)
AZT/3TC/NVP 32 (78.0) 9 (22.0) 41 (14.0)
AZT/3TC/EFV 54 (91.5) 5 (8.5) 59 (20.1)
TDF/3TC/EFV 2 (66.7) 1 (33.3) 3 (1.0)
Original Regimen substituted Yes 34 (16.8) 168 (83.2) 202 (68.9)
No 79 (87.8) 11 (12.2) 90 (30.7)
NR 0 1 1 (0.3)
Switch to second line regimen Yes 2 (33.3) 4 (66.7) 6 (2.0)
No 44 (15.3) 243 (84.7) 287 (98.0)
Baseline CD4 count, cells/mm3 Median, IQR 122 (67–190) 114 (63–176) 115 (64–176)
0–49 6 (12.8) 41 (87.2) 47 (16.2)
50–99 12 (16.0) 63 (84.0) 75 (25.9)
100–149 9 (14.3) 54 (85.7) 63 (21.7)
150–199 8 (12.9) 54 (87.1) 62 (21.4)
> = 200 10 (23.3) 33 (76.7) 43 (14.8)
Base line functional status Work 29 (15.9) 153 (84.1) 182 (62.1)
Ambulatory 9 (15.5) 49 (84.5) 58 (19.8)
Bedridden 3 (12.0) 22 (88.0) 25 (8.5)
NR 5 (17.9) 23 (82.1) 28 (9.6)
Body Mass Index. Kg/m2 <18.5 12 (18.8) 52 (81.2) 64 (21.8)
> = 18.5 15 (13.9) 93 (86.1) 108 (36.9)
NR 19 (15.7) 102 (84.3) 121 (41.3)
Gap between testing and treatment initiation Same month 29 (17.0) 142 (83.0) 171 (59.0)
1–24 months 13 (13.4) 84 (86.6) 97 (33.4)
>24 months 4 (18.2) 18 (81.8) 22 (7.6)
Adherence Good 35 (15.2) 195 (84.8) 230 (78.5)
Fair/ poor 10 (18.5) 44 (81.5) 54 (18.4)
NR 1 (11.1) 8 (88.9) 9 (3.1)
NR Not Recorded, IQR Interquartile Range, SD Standard Deviation
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risk of experiencing unfavorable outcome was 4.99 (95 %
CI 1.85, 13.44) times higher among those experiencing
immunological failure than their counterparts and it be-
came 5.75 (95 % CI 1.11, 29.8) times higher when ad-
justed for baseline CD4 count.
Discussion
In the present study, it was found that after a median
follow up duration of 70 months (IQR: 54–76 months),
15.7 % of the cohorts experienced immunological failure.
The failure rate of 3.0 per 100 PYO observed in our
study was slightly less than a study conducted in Haiti
which reported failure rate of 4.8 per 100 PYO [5]. This
could be because the Haiti study used both clinical and
immunological criteria to define treatment failure.
The overall switch rate to second-line regimen of
2.1 % in the current study is very low when compared
with other studies from resource-constrained settings
[5–10]. These studies reported that majority of the treat-
ment switch to second-line regimen was due to treat-
ment failure and not for treatment simplification [6–10].
The collaborative analysis of data from Zambia and
Malawi documented the overall switch rate of 13.4 %
among patients with immunological failure [11]; however,
in our study only 4.3 % (2/46) of such patients were
switched to second-line regimen. This indicates that
majority of patients with immunological failure weren’t
recognized and switched to second-line regimen in this
setting. A similar finding was documented by Keiser et al.
who argued that many patients who meet criteria for
treatment failure do not switch to second-line regimen
resulting in preventable deaths in Sub-Saharan Africa
countries [12].
In this study, around 96 % (44/46) of patients with im-
munological failure continued to take the already failed
first-line regimen. This finding was significantly different
from the report from Haiti where the health care sys-
tems detected 40 % and subsequently switched treat-
ment to second-line regimen [5]. This indicates presence
of a big gap in the quality of care being given as a large
proportion of treatment failures weren’t detected timely.
Despite the low positive predictive value and low sensi-
tivity of the immunological criteria to detect virologic
failure [13, 14], failure of the health system to detect and
switch treatment to second-line regimen for such pa-
tients will worsen the final outcome of HIV patients
with immunological failure.
In the current study, we noted that the risk of unfavor-
able outcome was significantly higher among immuno-
logically failed group. As this is a facility based document
review study, we couldn’t further verify the outcomes of
those who were lost from care. In order to control for this,
if we make the assumption that all patients who were lost
from care are alive, the risk of dying remains significantly
higher though the confidence interval becomes wide
owing to the sample size (OR 5.67, 95 % CI, 1.11, 29.04).
Previous studies conducted in Malawi to verify the true
outcome of lost patients indicated that around half of such
patients were found to be dead and remained undocu-
mented by the health system [15, 16].Other studies previ-
ously conducted in similar contexts documented higher
death rate among the immunologically failed group who
weren’t switched to second-line treatment [17, 18]. Timely
Fig. 2 Proportion of different follow up outcomes based on experience of immunological treatment failure
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switch to second-line regimen was also documented to
have a good viral suppression success rate [6] and also to
reduce mortality [12].
Diagnosis of treatment failure and timely regimen
switch to second-line may also act as a positive push fac-
tor for prevention of circulation of resistant viruses in the
community. A study conducted by Reynolds et al. found
that patients with immunological failure exhibit several
types of mutations [19]. The continuation of a failing regi-
men was also documented to result in rapid accumula-
tions of drug resistance [20]. The circulation of such
resistant viruses can have a negative impact on treatment
choice, as future patients may present with an already re-
sistant virus which implies that a structured approach for
treatment won’t be effective and initial treatment choice
will be based on resistance testing [21] which is a very
expensive approach in resource-limited settings.
Finally, the study may have limitations which could
affect generalization for the whole population on treat-
ment. In the first place many patients were excluded
from the cohort because their charts weren’t accessible
and/or they didn’t fulfill the inclusion criteria of having
at least four CD4 count measurements Kiraga et al. [22]
in a recent study have documented that ignoring such
outcomes could even over estimate the success of the
treatment programs.
Conclusion
In the current study, it was observed that majority of
patients with immunological treatment failures were not
detected and such patients continued to take the failed
regimen. The proportion of unfavorable outcome was
higher among the immunologically failed group. Further
studies are required to assess and explore why patients
with immunological treatment failure are not switched
to second-line regimen as per the standard protocol.
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